knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 23:02:39 - browse：191

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

entertainment

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

Why depression after traumatic brain injury is distinct

President Biden's budget: Here's what you might have missed

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

FAMU bans football players from facility after release of rap video shot in team's locker room

FDA advisers back CAR

entertainment

knowledge

explore

Cancer drug shortages should be causing more outrage

Medicare coverage of Wegovy, once blocked, now looks possible

Hollywood unions extend contract negotiations for actors

Statins reduce cardiovascular risk in people living with HIV

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

As demand for Covid shots wanes, Moderna seeks its next success

Inside the culture of fear in the White House science office of Eric Lander

After affirmative action ruling, medical educators look to 'holistic review'

EPA limits use of carcinogenic gas for sterilizing medical devices

Wikipedia

Pushing for an NIH office for post

How to protect coverage of PrEP

Steward Health Care Massachusetts hospitals face fiscal disaster

Medicare coverage of Wegovy, once blocked, now looks possible

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

explore

Wikipedia

entertainment

focus